Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?
作者信息
Distler Jörg H W, Distler Oliver
出版信息
Ann Rheum Dis. 2007 Jun;66(6):836. doi: 10.1136/ard.2006.067710.
Abstract
摘要
相似文献
1
Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?甲磺酸伊马替尼的心脏毒性：是极为罕见的现象还是主要副作用？
Ann Rheum Dis. 2007 Jun;66(6):836. doi: 10.1136/ard.2006.067710.
2
Transient respiratory failure possibly associated to imatinib.短暂性呼吸衰竭可能与伊马替尼有关。
Invest New Drugs. 2005 Mar;23(2):137-8. doi: 10.1007/s10637-005-5858-5.
3
Imatinib mesylate (gleevec) hepatotoxicity.
Dig Dis Sci. 2007 Feb;52(2):598-601. doi: 10.1007/s10620-006-9117-1. Epub 2007 Jan 12.
4
[Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].[伊马替尼致慢性髓性白血病患者暴发性肝炎]
Med Clin (Barc). 2011 Sep 17;137(7):329-30. doi: 10.1016/j.medcli.2010.09.011. Epub 2010 Nov 11.
5
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.伊马替尼与特发性嗜酸性粒细胞增多综合征中的心力衰竭
Ann Hematol. 2010 Jul;89(7):745-6. doi: 10.1007/s00277-009-0866-8. Epub 2009 Dec 2.
6
Adverse effects of imatinib--dissecting heart from the rest.伊马替尼的不良反应——剖析心脏与其他部位的差异。
Cancer. 2011 Jan 1;117(1):228; author reply 228-9. doi: 10.1002/cncr.25339. Epub 2010 Aug 30.
7
Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.甲磺酸伊马替尼致胃肠道间质瘤治疗患者发生急性肝炎
Eur J Gastroenterol Hepatol. 2006 Jul;18(7):785-7. doi: 10.1097/01.meg.0000216941.42306.0e.
8
Skin and oral lesions associated to imatinib mesylate therapy.
Support Care Cancer. 2009 Apr;17(4):465-8. doi: 10.1007/s00520-008-0536-8. Epub 2008 Nov 27.
9
Imatinib-induced bone edema: case report and review of literature.伊马替尼致骨水肿：病例报告及文献复习。
J Natl Compr Canc Netw. 2013 Oct 1;11(10):1187-91. doi: 10.6004/jnccn.2013.0140.
10
[Survival following liver transplant due to imatinib-induced acute liver failure: a case study].[伊马替尼诱导的急性肝衰竭肝移植后的生存情况：病例研究]
Farm Hosp. 2012 Jan-Feb;36(1):50-1. doi: 10.1016/j.farma.2010.12.004. Epub 2011 Apr 22.
引用本文的文献
1
Superior Antiproliferative and Enhanced Synergistic Effects of a ROCK Inhibitor in Multiple Models for Keloid Disease.ROCK抑制剂在瘢痕疙瘩疾病多种模型中的卓越抗增殖及增强协同效应
JID Innov. 2025 Jul 30;5(6):100402. doi: 10.1016/j.xjidi.2025.100402. eCollection 2025 Nov.
2
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy.小分子激酶抑制剂在癌症治疗中的心脏毒性
Exp Hematol Oncol. 2025 May 9;14(1):68. doi: 10.1186/s40164-025-00660-5.
3
Slowing Down the "Magic Bullet": Encapsulation of Imatinib in Fe-MOF for Cardiotoxicity Reduction and Improvement in Anticancer Activity.减缓“魔弹”：将伊马替尼包封在 Fe-MOF 中以降低心脏毒性并提高抗癌活性。
Molecules. 2024 Aug 12;29(16):3818. doi: 10.3390/molecules29163818.
4
Genome-wide assessment of shared genetic landscape of idiopathic pulmonary fibrosis and its comorbidities.全基因组评估特发性肺纤维化及其合并症的共享遗传特征。
Hum Genet. 2024 Oct;143(9-10):1223-1239. doi: 10.1007/s00439-024-02696-9. Epub 2024 Aug 6.
5
Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients.转移性胃肠间质瘤（GIST）的治疗：关注老年患者。
Drugs Aging. 2021 May;38(5):375-396. doi: 10.1007/s40266-021-00841-x. Epub 2021 Mar 2.
6
Cardiotoxicity of Novel Targeted Hematological Therapies.新型靶向血液学疗法的心脏毒性
Life (Basel). 2020 Dec 11;10(12):344. doi: 10.3390/life10120344.
7
Review of cardiotoxicity in pediatric cancer patients: during and after therapy.儿科癌症患者的心脏毒性回顾：治疗期间和治疗后。
Cardiol Res Pract. 2011;2011:942090. doi: 10.4061/2011/942090. Epub 2011 May 23.
8
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.系统性红斑狼疮与心血管疾病：预测及治疗干预的可能性。
Expert Rev Clin Immunol. 2011 Mar;7(2):227-41. doi: 10.1586/eci.10.98.
9
Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo.抗纤维化药物伊马替尼对体外和体内内皮细胞功能无抑制作用。
J Cell Mol Med. 2009 Oct;13(10):4185-91. doi: 10.1111/j.1582-4934.2008.00492.x.
本文引用的文献
1
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.甲磺酸伊马替尼可减少细胞外基质的产生，并预防实验性皮肤纤维化的发展。
Arthritis Rheum. 2007 Jan;56(1):311-22. doi: 10.1002/art.22314.
2
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.甲磺酸伊马替尼对酪氨酸激酶的选择性抑制作用用于治疗自身免疫性关节炎。
J Clin Invest. 2006 Oct;116(10):2633-42. doi: 10.1172/JCI28546. Epub 2006 Sep 14.
3
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.癌症治疗药物甲磺酸伊马替尼的心脏毒性。
Nat Med. 2006 Aug;12(8):908-16. doi: 10.1038/nm1446. Epub 2006 Jul 23.
4
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.尼洛替尼用于伊马替尼耐药的慢性粒细胞白血病和费城染色体阳性的急性淋巴细胞白血病。
N Engl J Med. 2006 Jun 15;354(24):2542-51. doi: 10.1056/NEJMoa055104.
5
Imatinib for the treatment of pulmonary arterial hypertension.伊马替尼用于治疗肺动脉高压。
N Engl J Med. 2005 Sep 29;353(13):1412-3. doi: 10.1056/NEJMc051946.
6
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.甲磺酸伊马替尼在晚期胃肠道间质瘤中的疗效与安全性。
N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461.
7
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.一种BCR-ABL酪氨酸激酶特异性抑制剂在慢性髓性白血病中的疗效与安全性
N Engl J Med. 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401.
8
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Abl酪氨酸激酶选择性抑制剂对Bcr-Abl阳性细胞生长的影响。
Nat Med. 1996 May;2(5):561-6. doi: 10.1038/nm0596-561.
Zotero 插件